Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107635 | 0.91 | CA2 (0.32) | CA12CA1CA2CA7CA14 | |
| SCHEMBL20695759 | 0.83 | LMNA (0.43) | — | |
| SCHEMBL23327896 | 0.83 | LMNA (0.43) | — | |
| SCHEMBL3039593 | 0.79 | METAP1 (0.33) | — | |
| SCHEMBL3034084 | 0.79 | TSHR (0.37) | — | |
| SCHEMBL3038189 | 0.79 | CYP3A4 (0.36) | CA12CA1CA2CA7CA14 | |
| SCHEMBL22342662 | 0.78 | CA12 (0.45) | CA12CA1CA2CA7CA14 | |
| SCHEMBL3042489 | 0.77 | CYP3A4 (0.39) | CA2 | |
| SCHEMBL3041309 | 0.76 | — | — | |
| SCHEMBL8794021 | 0.74 | CYP3A4 (0.39) | CA12CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | CA12 1258/4885CA1 2343/4885CA2 1345/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | CA12 1258/4885CA1 2343/4885CA2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.